Biotech IPO Pipeline & Valuation Analyzer

Reuters Legal News Desk: Drug developers Retension Pharmaceuticals and TRex Bio filed their paperwork for U.S. initial public offerings on Friday, reinforcing the biotech pipeline for the fall IPO window.

SEC Form S-1 Filings • Autumn Window

Filing Parameters

Adjust pipeline metrics, burn rates, and market window appetite

Active Filer Preset

Company Name

Lead Candidate / Modality

Fall IPO Window Sentiment 72%

Cautious (30%) Risk-On / Optimal (95%)

Target Gross Raise ($M) $120.0M

$40M $300M (Large Cap IPO)

Quarterly Net Burn ($M) $14.5M

Lean ($5.0M) Intensive ($40.0M)

Pre-Filing Balance Cash ($M) $106.3M

$20M $250M

Clinical Milestone Positivity 48%

Early Proof (20%) Registrational (85%)

Peak Annual Sales TAM ($M) $1,250M

Niche ($300M) Blockbuster ($5.0B)

Valuation Synthesis & Offering Readout

Risk-adjusted rNPV and secondary liquidity pricing model

RETN (Proposed)

Implied Enterprise Value

$450.0M

Derived from Phase 2 benchmark rNPV & 72% window sentiment

Cash Runway Status

Strong (22 mos)

Current cash covers clinical operations through milestone readout

Target IPO Raise

$120.0M

21.1% projected post-money primary dilution

Fall Window Readiness

Optimal (72% Sentiment)

Filing timing aligns with active institutional biotech bookbuilds

Milestone Success Progression & Post-IPO Runway Curve

Simulated cash depletion pre-IPO vs. pro-forma post-raise capital runway

Pro-Forma: 46 mos

Offering Breakdown & Share Pricing Matrix

Assumed 30M pre-money common shares outstanding

Component	Phase / Metric	Benchmark Rate	Valuation Impact
Lead Pipeline Asset	RT-204 (Phase 2)	48.0% PoS	$330.0M
Secondary Preclinical / Discovery	Targeted Platform	12.5% PoS	$65.0M
Net Fall Window Premium	Sentiment Multiplier	+1.12x	+$55.0M
Estimated Share Price Range	$14.00 - $16.00 / sh	Offering Size: 8.0M shares	$570.0M Cap